OTC:CODX
Co-Diagnostics, Inc.
A clinical diagnostics firm facing severe revenue contraction and persistent operating losses with a shrinking cash balance relative to its asset base.
Key Metrics
Investment Thesis
Bull Case
An investor might consider this stock if they believe the company can successfully pivot its product line or find a new market niche to reverse the severe revenue decline. The substantial cash and securities holdings could provide a runway for restructuring operations if management executes a viable turnaround plan effectively. Proprietary technology assets offer potential value if the company secures partnerships that monetize its intangible operating assets.
Bear Case
The stock presents a high risk of delisting or insolvency given the deepening losses, negative cash flow, and precipitous drop in annual revenue over the last three years. Investors should avoid this security due to the massive accumulated deficit and the inability to generate positive operating income despite significant R&D spending. The balance sheet shows a current liability position that is not fully covered by liquid assets when excluding marketable securities, raising concerns about immediate solvency.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc. operates within the clinical laboratory diagnostics sector, serving healthcare providers with point-of-care testing solutions and specialized diagnostic services. The company's recent financials reflect a significant contraction in operations, marked by substantial declines in revenue and deepening losses as it navigates market challenges. Key products likely include rapid testing kits or equipment used for infectious disease screening and other critical health assessments.
Analysis
Management Discussion
Management must address the dramatic deterioration in financial health, where revenue dropped by nearly 90% and net losses widened significantly year-over-year. Despite holding $26.8M in marketable securities, the company's operating cash flow turned negative, depleting its beginning cash reserves of $14.9M to ending levels of $2.9M. The heavy investment in research and development ($21.0M) alongside steep marketing costs ($4.5M) has failed to generate proportional revenue growth or profitability.
Industry Overview
The clinical diagnostics industry is highly competitive and sensitive to healthcare policy changes, supply chain disruptions, and emerging disease threats. Companies in this space require continuous innovation to maintain product relevance and regulatory approval from bodies like the FDA. Market consolidation is common as smaller players struggle with high customer acquisition costs and the need for expensive manufacturing facilities.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $34.2M | $6.8M | $3.9M |
| Cost of Revenue | $5.5M | $4.2M | $999.1K |
| Gross Profit | $28.7M | $2.6M | $2.9M |
| Operating Expenses | $55.7M | $45.3M | $43.0M |
| Operating Income | $-27.0M | $-42.7M | $-40.1M |
| R&D | $17.4M | $23.0M | $21.0M |
| G&A | $14.3M | $14.3M | $16.2M |
| Marketing | $7.3M | $6.9M | $4.5M |
| Stock-Based Comp | $7.5M | $8.3M | $5.4M |
| D&A | $1.3M | $1.2M | $1.4M |
| Other OpEx | $16.7M | $1.2M | $1.4M |
| Non-Operating Income | $8.1M | $4.6M | $2.5M |
| Interest Income | $704.0K | $1.2M | $1.1M |
| Pre-Tax Income | $-18.8M | $-38.1M | $-37.6M |
| Income Tax | $-4.6M | $-2.8M | $57.4K |
| Continuing Ops | $-14.2M | $-35.3M | $-37.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-14.2M | $-35.3M | $-37.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-14.2M | $-35.3M | $-37.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $92.7M | $62.1M | $32.3M |
| Cash & Equivalents | $23.0M | $14.9M | $2.9M |
| Marketable Securities | $58.3M | $43.6M | $26.8M |
| Accounts Receivable | $3.5M | $303.9K | $132.6K |
| Inventory | $5.3M | $1.7M | $1.1M |
| Prepaid Expenses | $761.2K | $1.6M | $1.3M |
| Other Current Assets | $1.9M | $27.0K | $0 |
| Long-Term Assets | $30.4M | $33.2M | $31.7M |
| PP&E (Net) | $2.5M | $3.0M | $2.8M |
| Intangibles | $26.8M | $26.4M | $26.1M |
| Operating Leases | $372.1K | $3.0M | $2.1M |
| Other LT Assets | $672.7K | $773.4K | $731.1K |
| Total Assets | $123.1M | $95.3M | $64.0M |
| Current Liabilities | $3.9M | $5.7M | $7.3M |
| Accounts Payable | $952.3K | $1.5M | $3.3M |
| Current Leases | $297.2K | $838.4K | $915.6K |
| Deferred Revenue | — | $362.4K | $40.9K |
| Other Current Liab | $1.7M | $891.7K | $502.8K |
| Long-Term Liabilities | $4.7M | $3.6M | $2.4M |
| LT Operating Leases | $50.7K | $2.2M | $1.2M |
| Other LT Liab | $4.6M | $1.4M | $1.1M |
| Total Liabilities | $8.6M | $9.3M | $9.7M |
| Shareholders' Equity | $114.5M | $86.0M | $54.3M |
| Paid-In Capital | $88.5M | $96.8M | $102.5M |
| Retained Earnings | $39.9M | $4.6M | $-33.0M |
| AOCI | $293.1K | $146.7K | $418.4K |
| Treasury Stock | $14.2M | $15.6M | $15.6M |
| Total L&E | $123.1M | $95.3M | $64.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-14.2M | $-35.3M | $-37.6M |
| Non-Cash Adjustments | $36.8M | $15.7M | $7.5M |
| Working Capital Changes | $-16.0M | $-2.4M | $1.0M |
| Cash from Operations | $6.6M | $-22.1M | $-29.2M |
| Capital Expenditures | $1.4M | $1.4M | $748.4K |
| Cash from Investing | $-58.2M | $15.4M | $17.1M |
| Share Buybacks | $14.2M | $1.4M | — |
| Cash from Financing | $-14.0M | $-1.4M | $103.9K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-65.6M | $-8.1M | $-12.0M |
| Beginning Cash | $88.6M | $23.0M | $14.9M |
| Ending Cash | $23.0M | $14.9M | $2.9M |
Frequently Asked Questions
How does Co-Diagnostics, Inc. make money?
Revenue is primarily derived from the sale of diagnostic testing materials, consumables, and potentially related medical equipment. The company also likely generates income through service fees for laboratory processing or partnerships with healthcare networks. A significant portion of expenses relates to general administration, marketing, and research and development, suggesting a segment focused on product innovation and market expansion despite current profitability issues.
What are the main risks for CODX?
The company faces an existential threat due to a massive negative operating cash flow of $29.2M and a net profit loss of $37.6M, indicating severe liquidity constraints. Revenue has collapsed from $34.2M in 2022 to just $3.9M in 2024, signaling a potential loss of market share or product viability. The retained earnings deficit stands at -$33.0M, highlighting a long history of losses that erodes the shareholder equity base. High general and administrative expenses relative to revenue suggest significant operational inefficiencies or cost overruns.
What is CODX's competitive advantage?
The company possesses proprietary intellectual property in the form of operating net intangible assets valued at $26.1M, which may include patents for specific diagnostic assays or technologies. Its established relationships with healthcare providers provide access to critical testing markets that are essential for public health monitoring. The presence of substantial marketable securities suggests a history of capital raising activities aimed at funding growth and R&D initiatives.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.